Nanotechnology-based strategies against SARS-CoV-2 variants

Xiangang Huang; Edo Kon; Xuexiang Han; Xingcai Zhang; Na Kong; Michael J. Mitchell; Dan Peer; Wei Tao

doi:10.1038/s41565-022-01174-5

Nanotechnology-based strategies against SARS-CoV-2 variants

Xiangang Huang
, Edo Kon
, Xuexiang Han
, Xingcai Zhang
, Na Kong
, Michael J. Mitchell^*
, Dan Peer^*
, Wei Tao^*

^*Corresponding author for this work

Harvard University
University of Pennsylvania

Research output: Contribution to journal › Article › peer-review

129 Scopus citations

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already infected more than 500 million people globally (as of May 2022), creating the coronavirus disease 2019 (COVID-19) pandemic. Nanotechnology has played a pivotal role in the fight against SARS-CoV-2 in various aspects, with the successful development of the two highly effective nanotechnology-based messenger RNA vaccines being the most profound. Despite the remarkable efficacy of mRNA vaccines against the original SARS-CoV-2 strain, hopes for quickly ending this pandemic have been dampened by the emerging SARS-CoV-2 variants, which have brought several new pandemic waves. Thus, novel strategies should be proposed to tackle the crisis presented by existing and emerging SARS-CoV-2 variants. Here, we discuss the SARS-CoV-2 variants from biological and immunological perspectives, and the rational design and development of novel and potential nanotechnology-based strategies to combat existing and possible future SARS-CoV-2 variants. The lessons learnt and design strategies developed from this battle against SARS-CoV-2 variants could also inspire innovation in the development of nanotechnology-based strategies for tackling other global infectious diseases and their future variants.

Original language	English
Pages (from-to)	1027-1037
Number of pages	11
Journal	Nature Nanotechnology
Volume	17
Issue number	10
DOIs	https://doi.org/10.1038/s41565-022-01174-5
State	Published - Oct 2022

Funding

Funders	Funder number
Innovation Authority in Israel
Director’s New Innovator Award
Scientific Interface
National Institutes of Health
Yoran Institute for Human Genome Research
Burroughs Wellcome Fund
Canadian Aeronautics and Space Institute
National Cancer Institute	R37CA244911, R01CA241661
American Heart Association	2018A004190
Nanotechnology Foundation	2022A002721
National Institute of Diabetes and Digestive and Kidney Diseases	R01DK123049
Farokhzad Family Distinguished Chair Foundation	018129
US METAvivor	113548, 2420 BPA075, 2020A003219, 2018A020560
National Center for Advancing Translational Sciences	DP2TR002776
Horizon 2020 Framework Programme	825828
National Science Foundation	CBET-2145491

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/s41565-022-01174-5

Cite this

@article{e950d70ec25248b58b9d7f5dea8b1168,

title = "Nanotechnology-based strategies against SARS-CoV-2 variants",

abstract = "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already infected more than 500 million people globally (as of May 2022), creating the coronavirus disease 2019 (COVID-19) pandemic. Nanotechnology has played a pivotal role in the fight against SARS-CoV-2 in various aspects, with the successful development of the two highly effective nanotechnology-based messenger RNA vaccines being the most profound. Despite the remarkable efficacy of mRNA vaccines against the original SARS-CoV-2 strain, hopes for quickly ending this pandemic have been dampened by the emerging SARS-CoV-2 variants, which have brought several new pandemic waves. Thus, novel strategies should be proposed to tackle the crisis presented by existing and emerging SARS-CoV-2 variants. Here, we discuss the SARS-CoV-2 variants from biological and immunological perspectives, and the rational design and development of novel and potential nanotechnology-based strategies to combat existing and possible future SARS-CoV-2 variants. The lessons learnt and design strategies developed from this battle against SARS-CoV-2 variants could also inspire innovation in the development of nanotechnology-based strategies for tackling other global infectious diseases and their future variants.",

author = "Xiangang Huang and Edo Kon and Xuexiang Han and Xingcai Zhang and Na Kong and Mitchell, \{Michael J.\} and Dan Peer and Wei Tao",

note = "Publisher Copyright: {\textcopyright} 2022, Springer Nature Limited.",

year = "2022",

month = oct,

doi = "10.1038/s41565-022-01174-5",

language = "אנגלית",

volume = "17",

pages = "1027--1037",

journal = "Nature Nanotechnology",

issn = "1748-3387",

publisher = "Nature Research",

number = "10",

}

TY - JOUR

T1 - Nanotechnology-based strategies against SARS-CoV-2 variants

AU - Huang, Xiangang

AU - Kon, Edo

AU - Han, Xuexiang

AU - Zhang, Xingcai

AU - Kong, Na

AU - Mitchell, Michael J.

AU - Peer, Dan

AU - Tao, Wei

PY - 2022/10

Y1 - 2022/10

N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already infected more than 500 million people globally (as of May 2022), creating the coronavirus disease 2019 (COVID-19) pandemic. Nanotechnology has played a pivotal role in the fight against SARS-CoV-2 in various aspects, with the successful development of the two highly effective nanotechnology-based messenger RNA vaccines being the most profound. Despite the remarkable efficacy of mRNA vaccines against the original SARS-CoV-2 strain, hopes for quickly ending this pandemic have been dampened by the emerging SARS-CoV-2 variants, which have brought several new pandemic waves. Thus, novel strategies should be proposed to tackle the crisis presented by existing and emerging SARS-CoV-2 variants. Here, we discuss the SARS-CoV-2 variants from biological and immunological perspectives, and the rational design and development of novel and potential nanotechnology-based strategies to combat existing and possible future SARS-CoV-2 variants. The lessons learnt and design strategies developed from this battle against SARS-CoV-2 variants could also inspire innovation in the development of nanotechnology-based strategies for tackling other global infectious diseases and their future variants.

AB - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already infected more than 500 million people globally (as of May 2022), creating the coronavirus disease 2019 (COVID-19) pandemic. Nanotechnology has played a pivotal role in the fight against SARS-CoV-2 in various aspects, with the successful development of the two highly effective nanotechnology-based messenger RNA vaccines being the most profound. Despite the remarkable efficacy of mRNA vaccines against the original SARS-CoV-2 strain, hopes for quickly ending this pandemic have been dampened by the emerging SARS-CoV-2 variants, which have brought several new pandemic waves. Thus, novel strategies should be proposed to tackle the crisis presented by existing and emerging SARS-CoV-2 variants. Here, we discuss the SARS-CoV-2 variants from biological and immunological perspectives, and the rational design and development of novel and potential nanotechnology-based strategies to combat existing and possible future SARS-CoV-2 variants. The lessons learnt and design strategies developed from this battle against SARS-CoV-2 variants could also inspire innovation in the development of nanotechnology-based strategies for tackling other global infectious diseases and their future variants.

UR - https://www.scopus.com/pages/publications/85136491530

U2 - 10.1038/s41565-022-01174-5

DO - 10.1038/s41565-022-01174-5

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 35982317

AN - SCOPUS:85136491530

SN - 1748-3387

VL - 17

SP - 1027

EP - 1037

JO - Nature Nanotechnology

JF - Nature Nanotechnology

IS - 10

ER -

Nanotechnology-based strategies against SARS-CoV-2 variants

Abstract

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this